62 results about "Blood flukes" patented technology

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention discloses an ecological regulation and control model for oncomelania indoor culture, and relates to the technical field of oncomelania culture regulation and control. Comprising the following steps: establishing a matching relationship between the number of indoor breeding units and the total oncomelania breeding amount for realizing standardized control of the initial oncomelania number of each breeding unit, ensuring the initial ecological balance of an experiment system, and determining the environment regulation priority of the indoor oncomelania breeding units based on the matching relationship. According to the method, the environmental parameter weight is dynamically corrected based on the risk intensity of different propagation stages of the schistosome, and the bottleneck that a static prevention and control strategy is difficult to adapt to the life cycle change of parasites is broken through; the biological rhythm of the oncomelania snail population can be accurately responded by environment regulation and control, the sustainability of indoor culture of the oncomelania snails is guaranteed to a certain extent, and the risk of schistosomiasis transmission is reduced.

The invention relates to a polypeptide capable of promoting tuft cell proliferation and application of the polypeptide in treatment of inflammatory bowel diseases, in particular to a polypeptide Sjp40-73 derived from schistosome egg protein, and the amino acid sequence of the polypeptide Sjp40-73 is SEQ ID NO.1. The invention further relates to a preparation method of the polypeptide Sjp40-73. The polypeptide can be obtained through methods such as genetic engineering expression or chemical synthesis. In-vitro experiments prove that the peptide can effectively increase the number of tuft cells of intestinal organs of mice; in-vivo experiments further prove that the peptide can relieve mouse inflammatory bowel diseases and can improve corresponding inflammations. The polypeptide prepared by the invention can be applied to medicines, health-care products or food additives for preventing and treating inflammatory enteritis.

This invention relates to compounds of formula (I), (II) and (III) and pharmaceutically acceptable salts or solvates thereof which impair viability of Schistosoma and Fasciola parasites. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates thereof and to the use of such compounds as medicaments, in particular in the treatment or prevention of a helminth infection such as in particular schistosomiasis, also known as bilharzia, and / or fascioliasis.

The invention relates to the technical field of medical information systems, and particularly discloses an early diagnosis data management system for a patient with schistosome hepatic fibrosis, which is used for acquiring blood biomarker data of the patient, and comparing and analyzing real-time blood biomarker data and historical blood biomarker data to obtain early diagnosis data of the patient with the schistosome hepatic fibrosis. Classifying the blood biomarker data into reliable data and unreliable data using a logistic regression model; calculating a variability deviation index and a logic deviation index of the blood biomarker data through a dynamic time warping and auto-encoder technology, and evaluating time stability and internal logic consistency of the blood biomarker data; performing normalization processing on the variability deviation index and the logic deviation index, and calculating an accuracy coefficient of the data; dividing the data into accurate data and inaccurate data according to the accuracy coefficient, and transmitting the accurate data to a patient management system.

The invention relates to the technical field of medicines, in particular to application of KLB protein in preparation of a medicine for treating schistosome infection. The invention verifies the treatment effect of the KLB protein on hepatic tissue EMT and fibrosis caused by schistosoma japonicum infection, and proves that the KLB can be used as a medicine for treating schistosoma japonicum hepatic fibrosis.

The invention discloses application of iron oxide nanoparticles in target treatment of schistosome eggs, and relates to the cross technical field of nano material target delivery and disease prevention and control. On the basis of paramagnetism, a microtubule structure and surface electrical characteristics of schistosoma japonicum egg shells, electrically neutral Fe3O4 magnetic nanoparticles with the particle size of 8-15 nm or electropositive Fe3O4-NH2 magnetic nanoparticles with the surface modified by amino groups are innovatively adopted, efficient egg penetration is achieved through magnetic targeted enrichment and physical-static synergistic effect, and in-vivo and in-vitro experiments prove that the effect of effectively penetrating through the eggs is achieved. The Fe3O4 and Fe3O4-NH2 nanoparticles have obvious worm egg targeting capability, and the penetrating efficiency of the Fe3O4 and Fe3O4-NH2 nanoparticles on worm eggs exceeds 38%, so that an important experimental basis is provided for subsequent development of a nano-drug delivery system for preventing and treating schistosomiasis.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The invention belongs to the technical field of medicine treatment, and particularly relates to application of combination of an organic small molecule compound and bivalent copper ions in preparation of a medicine for treating schistosomiasis japonicas. The invention provides an application of combination of an organic small molecule compound and bivalent copper ions in preparation of a medicine for treating schistosomiasis japonicas. The organic small molecule compound is selected from one or more of a compound with a structure as shown in a formula 1-1, a compound with a structure as shown in a formula 2-2 and a compound with a structure as shown in a formula 3. According to the invention, development of schistosoma japonicum at multiple juvenile stages in vivo can be blocked in a targeted manner through combination, the schistosoma load and the spawning rate are reduced, compared with praziquantel, the drug has better schistosoma killing activity, and preparation and application of the drug for treating schistosoma japonicum with efficient insect killing can be realized.

The present invention relates to a new vaccine candidate against schistosomiasis. This vaccine candidate is composed of peptides from different proteins of the parasite Schistosoma mansoni. Additionally, the present invention relates to use of the peptides for preparing a medicament for the prevention and / or treatment of schistosomiasis and to a method for preventing and / or treating schistosomiasis.

The present invention relates to a composition comprising a primer set for detecting or diagnosing Schistosoma and use thereof. When the composition of the present invention is used, it is possible to provide a diagnostic kit and a method for providing information for diagnosis, which can accurately, rapidly and effectively diagnose Schistosoma haematobium and Schistosoma mansoni, which account for the majority of schistosomiasis prevalence, without separate equipment and trained manpower. In addition, the present invention can be easily adopted in resource-constrained countries where schistosomiasis is prevalent, thereby contributing to enhancing the capacity for the diagnosis and management of Schistosoma infection.

The application discloses an ecological regulation model for indoor breeding of oncomelania, and relates to the technical field of snail breeding regulation. The model comprises a matching relationship between the number of indoor breeding units and the total amount of oncomelania breeding, which is used for realizing the standardized control of the initial oncomelania quantity of each breeding unit, ensuring the initial ecological balance of the experimental system, and determining the environmental regulation priority of the indoor oncomelania breeding unit based on the matching relationship. The application dynamically corrects the weight of the environmental parameter based on the risk intensity of different transmission stages of schistosoma, breaks through the bottleneck that the static prevention and control strategy is difficult to adapt to the change of the life cycle of parasites, and further realizes real-time monitoring of the fluctuation of biological characteristic parameters in the mating period, the pregnancy period and the reproductive period, so that the environmental regulation can accurately respond to the biological rhythm of the oncomelania population, ensures the sustainability of the indoor breeding of oncomelania to a certain extent, and reduces the risk of schistosomiasis transmission.

The application discloses an application of a nuclear receptor target gene in preparation of a biological preparation for blocking activation of diapause larvae, and relates to the field of biotechnology and parasite prevention and control. According to two nuclear receptor targets of Haemonchus contortus HCON_00101910 (regulating activity of worms) and HCON_00023750 (regulating development of larvae), the two nuclear receptor targets are combined with host progesterone and estradiol and are activated, constitute a key signal path in the spring activation process of diapause larvae, and have no homologous genes in mammals, and the safety is excellent. By constructing specific shRNA lentivirus vectors (the silencing efficiency is all greater than or equal to 60%) targeting the two genes, single target or double target synergistic intervention is realized, and the activity-development double key links of worms in the host body can be specifically blocked. The application provides a new paradigm of preventive prevention and control with high specificity and green safety, and provides core technical support for solving the seasonal epidemic problem of blood fluke disease.

The invention provides a long-acting slow-release compound preparation for preventing and treating schistosomiasis. The compound preparation comprises two active ingredients, namely niclosamide and praziquantel, the niclosamide accounts for 10-90% of the weight of the compound preparation; praziquantel accounts for 10%-90% of the weight of the compound preparation; the coating further comprises a biodegradable high polymer material and a dispersion medium. Optionally, a wetting agent; the biodegradable high polymer material accounts for 12.5%-14.3%; the dispersion medium accounts for 50.0%-57.1%; and the wetting agent accounts for 0-5.7%. The compound preparation can maintain long-acting slow release after being administrated once, has excellent prevention and control and treatment effects on schistosomiasis, particularly has good prevention and treatment effects on larvae and / or adults of schistosomiasis, blocks a transmission chain of the schistosomiasis, protects human beings and animals from schistosomiasis infection, and has huge economic benefits and social benefits.

Praziquantel may be formulated to enhance its pharmacokinetic, toxicity, and palatability properties. It can be stored and / or dispensed as a liquid, powder, or tablet. Reduction in the most common side effects improves patient compliance and satisfaction. Altered taste profile improves patient compliance and satisfaction. Once formulated it can be used to treat a variety of blood flukes and worms in human and veterinary subjects.

The invention relates to the technical field of bioengineering, in particular to a schistosoma japonicum miRNA simulant with an apoptosis function and an application of the schistosoma japonicum miRNA simulant. The invention relates to a schistosoma japonicum miRNA (micro Ribonucleic Acid) simulant, which is characterized in that the schistosoma japonicum miRNA simulant is a simulant designed aiming at a schistosoma japonicum miRNA molecule as sja-miR-2a-3p, and the nucleotide sequence of the sja-miR-2a-3p is TCACAGCCAGTATTGATGAACG. The research shows that the sja-miR-2a-3p and the simulant of the sja-miR-2a-3p disclosed by the invention are expected to become an innovative medicine for treating the hepatic fibrosis related to the schistosoma japonicum katsurada.

The invention provides a monoclonal antibody aiming at schistosoma japonicum SPRM1hc protein and application of the monoclonal antibody, and belongs to the technical fields of parasite infection treatment, biological medicine, immunotherapy and in-vitro diagnosis. The invention provides two monoclonal antibodies A028 and A032 which can be specifically combined with the extracellular domain of SPRM1hc protein, the actual effect of the monoclonal antibodies A028 and A032 in treatment of schistosoma japonicum katsurada after infection is verified, and the monoclonal antibodies A028 and A032 have a remarkable treatment effect in an infected animal model, and can reduce polypide load, reduce egg deposition and improve tissue pathological damage. The application of the monoclonal antibody to preparation of drugs for resisting schistosoma japonicum katsurada infection and development of schistosoma japonicum katsurada antigen detection kits has very important practical significance.

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.

The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein (rSm14) or homologous proteins of Fasciola hepatica (FhFABPs) that provide a homogeneous, long-term immune response against parasitic worms. The invention is also intended to provide a method for treating and preventing infection caused by parasitic worms, in particular Fasciola hepatica, and also the use of these proteins in a vaccine composition against parasitic worms.

The invention relates to application of aspirin in preparation of an anti-schistosoma japonicum medicine, and in the invention, by applying a schistosoma japonicum infection mouse model, the treatment effect of aspirin on schistosoma japonicum is found. Specifically, the aspirin can significantly reduce the number of insect bodies infected in mice and the number of eggs deposited in livers, and can effectively inhibit the antigen secretion ability of the eggs infected in the livers of the mice, the granuloma inflammation induced by the eggs and the hepatic fibrosis degree, so that the aspirin can be applied to treatment of schistosoma japonicum katsurada. And a new application of aspirin is added clinically. As a non-steroidal anti-inflammatory drug, aspirin is widely applied clinically, has the advantages of safety, reliability, stability, low cost, easiness in obtaining and the like, and is relatively deep in pharmacological research and relatively clear in action mechanism. Therefore, the scheme of the invention is suitable for clinical popularization and use.

The utility model belongs to the field of cercaria escape, particularly relates to a schistosome cercaria escape device, and aims to solve the problems that when oncomelania escape is carried out in the prior art, flowing of water flow in a real environment cannot be well simulated, an angle-adjustable illumination system cannot be arranged, the cercaria escape effect is poor, experimental equipment cannot be sterilized after an experiment is finished, and the working efficiency is low. In order to solve the problem that cercaria possibly remains in a box body and causes pollution, the utility model provides the following scheme: the device comprises a box body, supporting legs are fixedly connected to four corners of the bottom of the box body, a controller is arranged on the box body, a heater and a temperature sensor are arranged in the box body, and one side of the box body is fixedly communicated with a water inlet pipe; the top of the box body is open, a fixing plate is fixedly connected to the interior of the box body through bolts, natural water flow and illumination in different time periods can be well simulated through the disturbance mechanism and the adjusting mechanism, and the cercaria releasing process is accelerated.

The invention relates to the discovery of the virus consisting of Opisthorhabdovirus (ORV), Opisthorphenuilivirus (OPLV), Opisthorsivirus (OSV),Clonorsivirus (CSV), Clonorhabdovirus (CRV), Clonorphenuilivirus (CPLV), Schistohaemavirus (ShV), Schistohaematogalivirus (ShTLV), Schistohaemendornavirus (ShMV) and Schistorhabovirus (ShRV) from the Class I carcinogen trematodes Schistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis and provide evidence of fluke-borne infection of parasitized vertebrate hosts.. The invention provides viruses, nucleic acids, proteins, peptides, and antibodies useful for diagnosis, treatment, and prevention of viral infection and associated diseases.

The present invention discloses a kit for diagnosing schistosomiasis, which detects the hepatic granuloma and liver fibrosis induced by schistosome invasion by using the abundance changes of three bacteria, namely Bacteroides, Blautia, and Enterococcus, as intestinal flora biomarkers. Compared with traditional methods such as serological indicators, it has the advantages of high sensitivity, strong specificity, and non-invasiveness, thereby specifically detecting the degree of liver injury and achieving precise detection of schistosome-induced liver injury; compared with traditional blood detection methods such as AST and ALT, it is non-invasive and reduces contact with blood products; compared with imaging examinations such as B-ultrasound and CT, it has the advantages of portability and simplicity; the required equipment is simple, the test results are intuitive, the requirements for operators are low, it can effectively reduce the detection cost, and it is suitable for primary medical institutions and population screening sites.

The invention discloses a method for detecting schistosoma japonicum katsurada and host oncomelania of the schistosoma japonicum katsurada through fluorescent quantitative PCR (polymerase chain reaction) by using a double probe method. The target gene of the schistosoma japonicum katsurada is one of 16S rRNA (ribosomal ribonucleic acid), 18S small subunit rRNA gene, non-LTR (long-term transposon) retrotransposon SjCHGCS19 and non-LTR retrotransposon SjCHGCS20; the host oncomelania quality control gene is one of a COX1 gene, a 18S rRNA (ribosomal Ribonucleic Acid) gene and a 28S rRNA (ribosomal Ribonucleic Acid) gene. Preferably, the target gene of the schistosoma japonicum katsurada is the 18S small subunit rRNA gene, and the host oncomelania quality control gene is the 28S rRNA gene. The method can be used for rapidly and accurately detecting the schistosoma japonicum katsurada and the host oncomelania of the schistosoma japonicum katsurada, so that whether a detection sample is infected by the schistosoma japonicum katsurada or not can be rapidly judged, the schistosoma japonicum katsurada can also be used for evaluating the schistosoma japonicum katsurada spreading risk, and reference is provided for

The present invention relates to the field of molecular biology and biomedical technology, and in particular to a double-stranded RNA for killing schistosomes and its application. The double-stranded RNA is composed of a sense strand shown in SEQ ID NO.1 and an antisense strand shown in SEQ ID NO.2. Through animal in vivo experiments, it is confirmed that the double-stranded RNA can produce a significant killing effect on the worm body after schistosome infection. This double-stranded RNA can prevent schistosomes from establishing infection in the host body and inhibit the growth and development of the worm body. At the same time, it can also significantly reduce the egg-laying rate of female worms and kill the worm body that has established infection, thereby helping to reduce the host pathological damage caused by schistosome infection. Therefore, this double-stranded RNA is a highly potential schistosomiasis therapeutic agent, suitable for the treatment after schistosome infection and can provide new ideas for vaccine research and development.

The invention relates to a multiplex fluorescent polymerase chain reaction (PCR) method for detecting parasite pollution in a water body and application of the multiplex fluorescent polymerase chain reaction (PCR) method. According to the method, the existence of schistosoma japonicum katsurada, giardia giardia and hooked nematode duodenum in a water body is detected by utilizing a fluorescent quantitative PCR technology so as to evaluate whether the water body is polluted by the parasites or not. The method comprises the following steps: extracting environmental DNA of a to-be-detected sample, preparing a PCR amplification system containing a specific primer and a fluorescent probe, and detecting the 18s rRNA gene of a target parasite through a PCR amplification reaction. The method is rapid, sensitive and specific, and has important practical application value for evaluating and preventing water parasite pollution.

The invention discloses an application of baicalin in preparation of a medicine for inhibiting and / or treating schistosomiasis japonicas. The invention further discloses a medicine for inhibiting and / or treating schistosomiasis. Experiments prove that after praziquantel kills schistosoma japonicum adults, baicalin is used for treatment, so that liver and spleen injuries caused by schistosoma japonicum infection are effectively relieved, the liver function of a host is protected, the influence of eggs in the host and schistosoma japonicum egg protein secreted by the eggs on the host is reduced, and the survival rate of schistosoma japonicum adults is increased. The treatment effect of the praziquantel is obviously better than that of the existing praziquantel

The invention relates to a double-stranded ribonucleic acid composition for targeted inhibition of SjHAT1 expression and application of the double-stranded ribonucleic acid composition, and relates to the technical field of biological medicines. The method comprises the following steps: firstly, acquiring a full-length cDNA sequence of SjHAT1 by utilizing a cDNA terminal rapid amplification (RACE) technology in early-stage work, and accurately positioning a transcription condition and a distribution condition of the SjHAT1 gene in schistosoma japonicum adults by utilizing the acquired full-length cDNA sequence. Furthermore, according to the full-length cDNA sequence of the SjHAT1, the dsRNA composition for knocking down the SjHAT1 in a targeted mode is designed, the dsRNA composition can efficiently knock down the SjHAT1, the interference effect is good, the validity period is long, the treatment effect is better than that of a targeted drug DW-3-15, the dsRNA composition shows a good action effect in both in-vivo and in-vitro experiments, and the dsRNA composition has good application prospects. Wide application prospects are realized in the aspects of treatment of schistosomiasis, preparation of insecticides and the like.

The application belongs to the technical field of biological medicine, and relates to application of mucinophilic Akkermansia or outer vesicles thereof in preparation of a schistosomiasis treatment drug. The application enhances host anti-infection immunity by regulating intestinal flora balance (restoring diversity and composition), improving immune response (regulating macrophages, CD8+ T cell recruitment and Th1 / Th2 balance), improving intestinal barrier function, reducing pathogen invasion and inflammation, significantly reducing liver granuloma and liver fibrosis caused by schistosome infection, and improving liver function. The application reveals the key role of MIF gene in immune regulation, and provides a new direction for schistosomiasis immunotherapy. In addition, the probiotic treatment has high safety, no obvious side effects, can be combined with chemotherapy, enhances the curative effect, reduces the side effects of chemical drugs and drug resistance, provides a persistent and comprehensive adjuvant treatment scheme for schistosomiasis, and has important clinical application potential.

The present invention provides a targeted long noncoding double-stranded RNA, the nucleotide sequence of the sense strand of which is shown in SEQ ID NO: 1. This double-stranded RNA can inhibit the growth and development of schistosomes, reduce egg production, and effectively alleviate pathological damage to the host liver. The present invention also provides the use of this double-stranded RNA in the preparation of an anti-schistosomal drug. Animal experiments have shown that this double-stranded RNA has a significant inhibitory effect on the developmental stages of schistosomes, effectively inhibiting worm growth and development and female egg production, while also alleviating pathological damage to the host, demonstrating its significant application value and promising prospects.